sebaloxavir marboxil
Commercial- Indications
- Influenza
Company intelligence / Profile preview
Zenshine Pharmaceuticals
Nanjing, Jiangsu, Chinaen.zenshine-pharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Zenshine has filed an NDA for seloxavir marboxil for influenza in China (2024); ZX-7101A is in Phase 3 for influenza; ZX-4081 and ZX-8177 have IND approvals for oncology; other programs in preclinical stages
- Therapeutic areas
- Infectious DiseasesOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Jichuan Pharmaceutical (commercial strategic cooperation, 2023)
Beyond the preview
Go deeper on Zenshine Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zenshine Pharmaceuticals.